Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michael Klüver"'
Autor:
Anahita Fathi, Christine Dahlke, Verena Krähling, Alexandra Kupke, Nisreen M. A. Okba, Matthijs P. Raadsen, Jasmin Heidepriem, Marcel A. Müller, Grigori Paris, Susan Lassen, Michael Klüver, Asisa Volz, Till Koch, My L. Ly, Monika Friedrich, Robert Fux, Alina Tscherne, Georgia Kalodimou, Stefan Schmiedel, Victor M. Corman, Thomas Hesterkamp, Christian Drosten, Felix F. Loeffler, Bart L. Haagmans, Gerd Sutter, Stephan Becker, Marylyn M. Addo
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
In a clinical trial, Fathi et al. show that a booster vaccination with a vector vaccine candidate against the highly pathogenic Middle East Respiratory Syndrome coronavirus is safe and strongly improves the immunity generated by primary immunization.
Externí odkaz:
https://doaj.org/article/9c0741a645df4990aa04ffff02338df4
Autor:
Meryem Seda Ercanoglu, Lutz Gieselmann, Sabrina Dähling, Nareshkumar Poopalasingam, Susanne Detmer, Manuel Koch, Michael Korenkov, Sandro Halwe, Michael Klüver, Veronica Di Cristanziano, Hanna Janicki, Maike Schlotz, Johanna Worczinski, Birgit Gathof, Henning Gruell, Matthias Zehner, Stephan Becker, Kanika Vanshylla, Christoph Kreer, Florian Klein
Publikováno v:
iScience, Vol 25, Iss 3, Pp 103951- (2022)
Summary: Preexisting immunity against SARS-CoV-2 may have critical implications for our understanding of COVID-19 susceptibility and severity. The presence and clinical relevance of a preexisting B cell immunity remain to be fully elucidated. Here, w
Externí odkaz:
https://doaj.org/article/2404de6fd5954a088328929e1de3cfe8
Autor:
Anne Sadewasser, Erik Dietzel, Sven Michel, Michael Klüver, Markus Helfer, Tamara Thelemann, Richard Klar, Markus Eickmann, Stephan Becker, Frank Jaschinski
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 16, Iss , Pp 686-697 (2019)
Ebola virus is the causative agent of Ebola virus disease, a severe, often fatal illness in humans. So far, there are no US Food and Drug Administration (FDA)-approved therapeutics directed against Ebola virus. Here, we selected the host factor Niema
Externí odkaz:
https://doaj.org/article/308c7be2e7a44d74b79da85945b8925c
Autor:
Sandro Halwe, Alexandra Kupke, Kanika Vanshylla, Falk Liberta, Henning Gruell, Matthias Zehner, Cornelius Rohde, Verena Krähling, Michelle Gellhorn Serra, Christoph Kreer, Michael Klüver, Lucie Sauerhering, Jörg Schmidt, Zheng Cai, Fei Han, David Young, Guangwei Yang, Marek Widera, Manuel Koch, Anke Werner, Lennart Kämper, Nico Becker, Michael S. Marlow, Markus Eickmann, Sandra Ciesek, Felix Schiele, Florian Klein, Stephan Becker
Publikováno v:
Viruses, Vol 13, Iss 8, p 1498 (2021)
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the g
Externí odkaz:
https://doaj.org/article/a952a8244dfc4b74bafbb2519784edf5
Autor:
Meryem Seda Ercanoglu, Lutz Gieselmann, Sabrina Dähling, Nareshkumar Poopalasingam, Susanne Detmer, Manuel Koch, Michael Korenkov, Sandro Halwe, Michael Klüver, Veronica Di Cristanziano, Hanna Janicki, Maike Schlotz, Johanna Worczinski, Birgit Gathof, Henning Gruell, Matthias Zehner, Stephan Becker, Kanika Vanshylla, Christoph Kreer, Florian Klein
Publikováno v:
iScience. 25(3)
Preexisting immunity against SARS-CoV-2 may have critical implications for our understanding of COVID-19 susceptibility and severity. The presence and clinical relevance of a preexisting B cell immunity remain to be fully elucidated. Here, we provide
Autor:
Markus Eickmann, Anne Sadewasser, Tamara Thelemann, Frank Jaschinski, Sven Michel, Michael Klüver, Erik Dietzel, Stephan Becker, Richard Klar, Markus Helfer
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 16, Iss, Pp 686-697 (2019)
Molecular Therapy: Nucleic Acids, Vol 16, Iss, Pp 686-697 (2019)
Ebola virus is the causative agent of Ebola virus disease, a severe, often fatal illness in humans. So far, there are no US Food and Drug Administration (FDA)-approved therapeutics directed against Ebola virus. Here, we selected the host factor Niema